120 related articles for article (PubMed ID: 20417098)
21. Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists.
Rotstein DM; Gabriel SD; Manser N; Filonova L; Padilla F; Sankuratri S; Ji C; deRosier A; Dioszegi M; Heilek G; Jekle A; Weller P; Berry P
Bioorg Med Chem Lett; 2010 Jun; 20(11):3219-22. PubMed ID: 20457517
[TBL] [Abstract][Full Text] [Related]
22. Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.
Shankaran K; Donnelly KL; Shah SK; Guthikonda RN; MacCoss M; Mills SG; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Carella A; Carver G; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
Bioorg Med Chem Lett; 2004 Jul; 14(13):3419-24. PubMed ID: 15177445
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
Imamura S; Ichikawa T; Nishikawa Y; Kanzaki N; Takashima K; Niwa S; Iizawa Y; Baba M; Sugihara Y
J Med Chem; 2006 May; 49(9):2784-93. PubMed ID: 16640339
[TBL] [Abstract][Full Text] [Related]
24. CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.
Imamura S; Kurasawa O; Nara Y; Ichikawa T; Nishikawa Y; Iida T; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2004 May; 12(9):2295-306. PubMed ID: 15080927
[TBL] [Abstract][Full Text] [Related]
25. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
Seto M; Miyamoto N; Aikawa K; Aramaki Y; Kanzaki N; Iizawa Y; Baba M; Shiraishi M
Bioorg Med Chem; 2005 Jan; 13(2):363-86. PubMed ID: 15598559
[TBL] [Abstract][Full Text] [Related]
26. CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives.
Lu SF; Chen B; Davey D; Dunning L; Jaroch S; May K; Onuffer J; Phillips G; Subramanyam B; Tseng JL; Wei RG; Wei M; Ye B
Bioorg Med Chem Lett; 2007 Apr; 17(7):1883-7. PubMed ID: 17314043
[TBL] [Abstract][Full Text] [Related]
27. The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies.
Armour D; de Groot MJ; Edwards M; Perros M; Price DA; Stammen BL; Wood A
ChemMedChem; 2006 Jul; 1(7):706-9. PubMed ID: 16902922
[No Abstract] [Full Text] [Related]
28. Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles.
Nishizawa R; Nishiyama T; Hisaichi K; Hirai K; Habashita H; Takaoka Y; Tada H; Sagawa K; Shibayama S; Maeda K; Mitsuya H; Nakai H; Fukushima D; Toda M
Bioorg Med Chem Lett; 2010 Jan; 20(2):763-6. PubMed ID: 20005712
[TBL] [Abstract][Full Text] [Related]
29. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.
Duan M; Aquino C; Ferris R; Kazmierski WM; Kenakin T; Koble C; Wheelan P; Watson C; Youngman M
Bioorg Med Chem Lett; 2009 Mar; 19(6):1610-3. PubMed ID: 19233649
[TBL] [Abstract][Full Text] [Related]
30. Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.
Shankaran K; Donnelly KL; Shah SK; Caldwell CG; Chen P; Finke PE; Oates B; MacCoss M; Mills SG; DeMartino JA; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Kwei G; Carella A; Carver G; Danzeisen R; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
Bioorg Med Chem Lett; 2004 Jul; 14(13):3589-93. PubMed ID: 15177481
[TBL] [Abstract][Full Text] [Related]
31. Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists.
Palani A; Tagat JR
J Med Chem; 2006 May; 49(10):2851-7. PubMed ID: 16686527
[No Abstract] [Full Text] [Related]
32. Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
Nishizawa R; Nishiyama T; Hisaichi K; Matsunaga N; Minamoto C; Habashita H; Takaoka Y; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
Bioorg Med Chem Lett; 2007 Feb; 17(3):727-31. PubMed ID: 17118654
[TBL] [Abstract][Full Text] [Related]
33. Tricyclic HIV integrase inhibitors: VI. SAR studies of 'benzyl flipped' C3-substituted pyrroloquinolines.
Metobo S; Mish M; Jin H; Jabri S; Lansdown R; Chen X; Tsiang M; Wright M; Kim CU
Bioorg Med Chem Lett; 2009 Feb; 19(4):1187-90. PubMed ID: 19167883
[TBL] [Abstract][Full Text] [Related]
34. Novel tetrahydropyrido[3,2-c]pyrroles as 5-HT(7) antagonists.
Rudolph DA; Dvorak CA; Dvorak L; Nepomuceno D; Bonaventure P; Lovenberg TW; Carruthers NI
Bioorg Med Chem Lett; 2011 Jan; 21(1):42-4. PubMed ID: 21159507
[TBL] [Abstract][Full Text] [Related]
35. Discovery of 1,3-disubstituted-1H-pyrrole derivatives as potent melanin-concentrating hormone receptor 1 (MCH-R1) antagonists.
Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
Bioorg Med Chem Lett; 2008 Sep; 18(17):4859-63. PubMed ID: 18682323
[TBL] [Abstract][Full Text] [Related]
36. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
Shen DM; Shu M; Willoughby CA; Shah S; Lynch CL; Hale JJ; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):941-5. PubMed ID: 15012998
[TBL] [Abstract][Full Text] [Related]
37. Clustering and classifying diverse HIV entry inhibitors using a novel consensus shape-based virtual screening approach: further evidence for multiple binding sites within the CCR5 extracellular pocket.
Pérez-Nueno VI; Ritchie DW; Borrell JI; Teixidó J
J Chem Inf Model; 2008 Nov; 48(11):2146-65. PubMed ID: 18942828
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent.
Ma D; Yu S; Li B; Chen L; Chen R; Yu K; Zhang L; Chen Z; Zhong D; Gong Z; Wang R; Jiang H; Pei G
ChemMedChem; 2007 Feb; 2(2):187-93. PubMed ID: 17163560
[TBL] [Abstract][Full Text] [Related]
39. Design and optimisation of potent gp120-CD4 inhibitors.
Tran TD; Adam FM; Calo F; Fenwick DR; Fok-Seang J; Gardner I; Hay DA; Perros M; Rawal J; Middleton DS; Parkinson T; Pickford C; Platts M; Randall A; Stephenson PT; Vuong H; Williams DH
Bioorg Med Chem Lett; 2009 Sep; 19(17):5250-5. PubMed ID: 19632839
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.
Shah SK; Chen N; Guthikonda RN; Mills SG; Malkowitz L; Springer MS; Gould SL; Demartino JA; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Emini EA; MacCoss M
Bioorg Med Chem Lett; 2005 Feb; 15(4):977-82. PubMed ID: 15686896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
